neurocoach.
My Care Plan
Explore optionsMedications

MEDICATIONS

Ecopipam (investigational Tourette medication)

Selective dopamine D1 antagonist with promising randomized pediatric tic findings; under FDA Priority Review, not yet approved.

NeuroCoach · Evidence explorerSources checked 2026-10-11Editorial draft · clinical review pending

How it works

Ecopipam selectively blocks dopamine D1 receptors, a mechanism distinct from many medications used for tics. It is under investigation for Tourette syndrome.

What the evidence says, use by use

Evidence is specific to the condition, population and—for devices—the exact product. One label never covers everything.

Tourette Syndrome & Tic Disorders: Reducing and maintaining improvement in troublesome tics

Promising
Who was studied / who it’s for: Primarily children and adolescents with Tourette syndrome; adult findings exploratoryRegulatory status: Investigational, not FDA approved as of October 11, 2026. NDA accepted for Priority Review, with FDA action targeted for late Q1 2027.What this label means: Meaningful evidence exists for this use, but important questions remain—about size of benefit, who benefits, or long-term effects.

In the 2026 JAMA Neurology Phase 3 randomized-withdrawal trial, pediatric responders who continued ecopipam had less tic relapse than those switched to placebo (hazard ratio 0.47). October post hoc analyses reported that about 70% of pooled trial participants had at least 25% tic-score improvement within eight weeks, but these analyses cannot predict an individual's chance of benefit.

Sources: Gilbert et al., JAMA Neurology (May 26, 2026) · Teva Pharmaceuticals (October 2, 2026) · Teva Pharmaceuticals (August 19, 2026)

Who usually provides it

Research investigators and, if eventually authorized, specialist prescribers; FDA-approved availability has not been established.

Cautions & things to know

  • October's 18-month extension was open-label and uncontrolled; it cannot establish long-term comparative effectiveness or safety.
  • Sleepiness, anxiety, headaches, insomnia and fatigue were reported in studies; individual risks require clinical review.
  • CBIT remains an evidence-based option and accommodations may be enough for non-impairing tics. Do not obtain research drugs outside legitimate clinical trials.

Questions for a clinician

Conversation prompts, not a treatment plan.

  • Is CBIT appropriate and accessible before or alongside medication?
  • What is the current FDA status, age indication, safety information and trial availability?
  • Which changes in tics, comfort, participation and side effects would we measure?

Educational, not medical advice. NeuroCoach is an educational and care-navigation resource, not a medical provider. Information about medications, supplements, therapies, devices, clinical trials and community experiences is provided for education and exploration and is not a recommendation, diagnosis or treatment plan. Evidence varies substantially among interventions. Decisions about medical or mental-health treatment should be made with an appropriately qualified healthcare professional. Do not start, stop or change medication, supplements or treatment based solely on information found here.

Sources

Sources checked 2026-10-11. Educational editorial draft; clinical review pending.

  1. Phase 3 randomized-withdrawal Tourette trial Gilbert et al., JAMA Neurology (May 26, 2026)
  2. Post hoc and open-label extension ecopipam Tourette analyses Teva Pharmaceuticals (October 2, 2026)
  3. FDA accepts ecopipam NDA for Priority Review Teva Pharmaceuticals (August 19, 2026)